Quick Answer
FENNEC PHARMACEUTICALS INC. reported Operating Income Loss of -$6.28 million for the year ending 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -344.6% in Operating Income Loss from 2024 to 2025.
- This data is from FENNEC PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), FENNEC PHARMACEUTICALS INC.'s Operating Income Loss has declined by 36.4%.
- Historical annual values: Fiscal year 2025: -$6.28 million | Fiscal year 2024: $2.57 million | Fiscal year 2023: -$12.77 million | Fiscal year 2022: -$22.59 million | Fiscal year 2021: -$17.22 million | Fiscal year 2020: -$17.89 million | Fiscal year 2019: -$13.01 million | Fiscal year 2018: -$10.41 million | Fiscal year 2017: -$6.95 million | Fiscal year 2016: -$2.87 million | Fiscal year 2015: -$1.89 million | Fiscal year 2014: -$2.88 million | Fiscal year 2013: -$1.93 million | Fiscal year 2012: -$3.62 million | Fiscal year 2011: -$3.44 million | Fiscal year 2010: -$4.60 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: